title: An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP.
abstract: Two hundred and twenty seven patients with stage IIIA-IVB Hodgkin's disease have been treated at a single centre with MVPP chemotherapy followed by radiotherapy to sites of previously bulk disease. The median follow up is 58 months. 119 patients (52%) had stage IV disease. Overall complete remission (CR) rate was 72%. Discriminant analysis of factors predictive for complete remission showed that low albumin was the only independent factor that predicted a significantly lower chance of CR. Overall five year survival was 73%. A Cox multivariate analysis demonstrated that age greater than 40 years, stage IV disease, presence of bulk disease, low serum IgG and male sex to be variables which independently predicted poorer prognosis in terms of overall survival. Stage IV and lymphocyte depleted or unclassified histologies were independently predictive for poorer progression-free survival. Patient weight greater than 70 kg and stage IV disease were adverse prognostic factors for relapse free survival. Results are compared to other published multivariate analyses of prognostic factors in advanced Hodgkin's disease.
authors.affiliation: Department of Medical Oncology, CRC University of Manchester, UK.
authors.forename: M R
authors.initials: MR
authors.lastname: Ranson
authors.forename: J A
authors.initials: JA
authors.lastname: Radford
authors.forename: R
authors.initials: R
authors.lastname: Swindell
authors.forename: D P
authors.initials: DP
authors.lastname: Deakin
authors.forename: P M
authors.initials: PM
authors.lastname: Wilkinson
authors.forename: M
authors.initials: M
authors.lastname: Harris
authors.forename: R J
authors.initials: RJ
authors.lastname: Johnson
authors.forename: D
authors.initials: D
authors.lastname: Crowther
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016002:Discriminant Analysis; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D011239:Prednisolone